This reminds me, tangentially, of JD Vance agreeing that "the whole purpose of the postmenopausal female" (!) is to raise grandchildren, because obviously there needs to be an explanation for postmenopausal women existing at all. All transphobia is misogyny.
November 2, 2026 at 2:37 PM
This reminds me, tangentially, of JD Vance agreeing that "the whole purpose of the postmenopausal female" (!) is to raise grandchildren, because obviously there needs to be an explanation for postmenopausal women existing at all. All transphobia is misogyny.
Ever wonder why period pieces are so popular with postmenopausal women?
October 28, 2026 at 12:32 AM
Ever wonder why period pieces are so popular with postmenopausal women?
Factors associated with postmenopausal migraine persistence: A retrospective tertiary headache clinic-based study
▶️ Read Full Paper
📚 Source: Headache
👤 Creator: Amr Hassan et al.
📅 Date: 2026-11-03
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
▶️ Read Full Paper
📚 Source: Headache
👤 Creator: Amr Hassan et al.
📅 Date: 2026-11-03
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
Factors associated with postmenopausal migraine persistence: A retrospective tertiary headache clinic-based study
CONCLUSION: Migraine showed overall improvement in severity and frequency if it persisted after menopause. Persistence was associated with a first-degree relative with migraine and insomnia. Surgical menopause also showed an association, but this estimate was imprecise due to ...
pubmed.ncbi.nlm.nih.gov
November 3, 2026 at 5:22 PM
Factors associated with postmenopausal migraine persistence: A retrospective tertiary headache clinic-based study
▶️ Read Full Paper
📚 Source: Headache
👤 Creator: Amr Hassan et al.
📅 Date: 2026-11-03
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
▶️ Read Full Paper
📚 Source: Headache
👤 Creator: Amr Hassan et al.
📅 Date: 2026-11-03
#MigrainePapertag/MigrainePaper" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#MigrainePaper #Migraine/hashtag/Migraine" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#Migraine #PubMed="/hashtag/PubMed" class="hover:underline text-blue-600 dark:text-sky-400 no-card-link">#PubMed
Yup, you're all postmenopausal women now.
See us for advice.
See us for advice.
They think of us the way factory egg farmers think about chickens - how little space, food, air, and water can they give us and still get eggs? And then what's the most efficient way to dispose of us once we stop producing eggs?
November 2, 2026 at 11:59 PM
Yup, you're all postmenopausal women now.
See us for advice.
See us for advice.
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal women. Read more in #JCEM: https://bit.ly/4iU2GxM #estradiol @endocrinesociety.bsky.social
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal women
AbstractContext. Prior reports of plasma estradiol concentrations and their reference ranges in postmenopausal women identified marked variation, in part d
bit.ly
November 4, 2026 at 1:54 AM
Establishment of harmonized international reference ranges for plasma estradiol concentrations in postmenopausal women. Read more in #JCEM: https://bit.ly/4iU2GxM #estradiol @endocrinesociety.bsky.social
Takotsubo syndrome predominantly affects postmenopausal women, who account for roughly 90% of all reported cases. It is thought that the decline in protective estrogen levels increases myocardial sensitivity to surge-level catecholamines. #medsky
November 1, 2026 at 1:59 AM
Takotsubo syndrome predominantly affects postmenopausal women, who account for roughly 90% of all reported cases. It is thought that the decline in protective estrogen levels increases myocardial sensitivity to surge-level catecholamines. #medsky
PXD061120 🚨
Postmenopausal female subjects with knee osteoarthritis report worse pain compared to male subjects of similar age and radiographic score.
🚨 New dataset alert! 🚨
Postmenopausal female subjects with knee osteoarthritis report worse pain compared to male subjects of similar age and radiographic score.
🚨 New dataset alert! 🚨
October 30, 2026 at 11:00 PM
PXD061120 🚨
Postmenopausal female subjects with knee osteoarthritis report worse pain compared to male subjects of similar age and radiographic score.
🚨 New dataset alert! 🚨
Postmenopausal female subjects with knee osteoarthritis report worse pain compared to male subjects of similar age and radiographic score.
🚨 New dataset alert! 🚨
110 postmenopausal women, sleep measured in a lab. Elinzanetant cut time awake after falling asleep by 22.50 minutes at week 4. By week 12 the difference was -0.94 minutes.
A menopause sleep drug worked at week 4, then didn't
A SLEEP trial gave 110 postmenopausal women elinzanetant or placebo and measured sleep in a lab. The 22-minute advantage at four weeks had vanished by twelve.
livewellnews.com
November 4, 2026 at 3:20 PM
110 postmenopausal women, sleep measured in a lab. Elinzanetant cut time awake after falling asleep by 22.50 minutes at week 4. By week 12 the difference was -0.94 minutes.
FYI: Study Finds Less Drinking After Breast Cancer Diagnosis Did Not Lower Mortality #BreastCancer #CancerResearch #HealthStudies #Postmenopausal #AlcoholConsumption
Study Finds Less Drinking After Breast Cancer Diagnosis Did Not Lower Mortality
Researchers tracked 1,558 postmenopausal women in an observational analysis that addressed survival after diagnosis rather than cancer risk
www.vinetur.com
October 29, 2026 at 12:25 PM
FYI: Study Finds Less Drinking After Breast Cancer Diagnosis Did Not Lower Mortality #BreastCancer #CancerResearch #HealthStudies #Postmenopausal #AlcoholConsumption
Among women with vasomotor symptoms, #MenopausalHormoneTherapy initiation was associated with lower #CardiovascularDisease risk vs noninitiation, with lower risk estimates among women who initiated therapy within 10 years of menopause. ja.ma/47VwQdQ
Menopausal Hormone Therapy and Cardiovascular Risk in Midlife Women With Vasomotor Symptoms
This target trial emulation evaluates the effect of menopausal hormone therapy on cardiovascular risk among perimenopausal and recently postmenopausal women with vasomotor symptoms.
ja.ma
November 4, 2026 at 11:00 AM
Among women with vasomotor symptoms, #MenopausalHormoneTherapy initiation was associated with lower #CardiovascularDisease risk vs noninitiation, with lower risk estimates among women who initiated therapy within 10 years of menopause. ja.ma/47VwQdQ
For peri- and post-menopausal women with chronic insomnia, Cognitive Behavioural Therapy for Insomnia and other non-drug approaches currently have stronger evidence and may be preferable to medication as first-line treatment options!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Pharmacological and non-pharmacological treatments for chronic insomnia in perimenopausal and postmenopausal women: a systematic review and meta-analysis
Chronic insomnia is highly prevalent during menopause, with or without vasomotor symptoms, and is associated with significantly impaired quality of li…
www.sciencedirect.com
November 2, 2026 at 9:13 AM
For peri- and post-menopausal women with chronic insomnia, Cognitive Behavioural Therapy for Insomnia and other non-drug approaches currently have stronger evidence and may be preferable to medication as first-line treatment options!
www.sciencedirect.com/science/arti...
www.sciencedirect.com/science/arti...
Patients were classified as having persistent or resolved migraine after menopause. Premenopausal migraine severity and frequency, measured using a visual analog scale and monthly migraine days, were extracted from the database for comparison with postmenopausal values. (🧵 4/10)
November 3, 2026 at 5:22 PM
Patients were classified as having persistent or resolved migraine after menopause. Premenopausal migraine severity and frequency, measured using a visual analog scale and monthly migraine days, were extracted from the database for comparison with postmenopausal values. (🧵 4/10)
Myth: HRT prevents frozen shoulder. In records of 1,952 postmenopausal women aged 40 to 60, 7.65% off hormone therapy had it, vs 3.95% on it (Reinke et al., Climacteric, 2026). We'd like that. But only 152 were on hormones, so the gap may be chance, and the authors want bigger studies.
November 3, 2026 at 4:23 PM
Myth: HRT prevents frozen shoulder. In records of 1,952 postmenopausal women aged 40 to 60, 7.65% off hormone therapy had it, vs 3.95% on it (Reinke et al., Climacteric, 2026). We'd like that. But only 152 were on hormones, so the gap may be chance, and the authors want bigger studies.
Postmenopausal Vaginal Atrophy (PVA) Drug Market Report 2035 www.marketresearchfuture.com/reports/post...
Postmenopausal Vaginal Atrophy (PVA) Drug Market Report 2035
Postmenopausal Vaginal Atrophy Drug Market to reach USD 4.46 Billion by 2035, growing at 8.31% CAGR. Explore size, share, companies, segments & forecast 2025–2035.
www.marketresearchfuture.com
October 29, 2026 at 5:30 PM
Postmenopausal Vaginal Atrophy (PVA) Drug Market Report 2035 www.marketresearchfuture.com/reports/post...
The sleep hygiene list was finally tested on women like us.
150 postmenopausal women with chronic insomnia. Cool dark room, same bedtime, no caffeine, the whole pamphlet. It fixed about 4 in 100.
How many of you were handed that list and sent home?
🫶
Kay
#Menopause
150 postmenopausal women with chronic insomnia. Cool dark room, same bedtime, no caffeine, the whole pamphlet. It fixed about 4 in 100.
How many of you were handed that list and sent home?
🫶
Kay
#Menopause
October 31, 2026 at 1:07 PM
The sleep hygiene list was finally tested on women like us.
150 postmenopausal women with chronic insomnia. Cool dark room, same bedtime, no caffeine, the whole pamphlet. It fixed about 4 in 100.
How many of you were handed that list and sent home?
🫶
Kay
#Menopause
150 postmenopausal women with chronic insomnia. Cool dark room, same bedtime, no caffeine, the whole pamphlet. It fixed about 4 in 100.
How many of you were handed that list and sent home?
🫶
Kay
#Menopause
Despite persistence, postmenopausal assessments showed significant reductions in median visual analog scale scores (7.0 [6.0-8.0] vs. 6.0 [4.0-7.0]), median monthly migraine days (8.0 [5.0-14.0] vs. 6.0 [3.0-10.0]), and the proportion of patients reporting aura (🧵 6/10)
November 3, 2026 at 5:22 PM
Despite persistence, postmenopausal assessments showed significant reductions in median visual analog scale scores (7.0 [6.0-8.0] vs. 6.0 [4.0-7.0]), median monthly migraine days (8.0 [5.0-14.0] vs. 6.0 [3.0-10.0]), and the proportion of patients reporting aura (🧵 6/10)
(134/219 [61.2%] vs. 116/219 [53.0%]) (all p ＜ 0.01) compared with the premenopausal period. Factors associated with postmenopausal migraine persistence are a first-degree relative with migraine (adjusted odds ratio [aOR] = 1.92, 95% CI = 1.07-3.43, p = 0.029), insomnia (🧵 7/10)
November 3, 2026 at 5:22 PM
(134/219 [61.2%] vs. 116/219 [53.0%]) (all p ＜ 0.01) compared with the premenopausal period. Factors associated with postmenopausal migraine persistence are a first-degree relative with migraine (adjusted odds ratio [aOR] = 1.92, 95% CI = 1.07-3.43, p = 0.029), insomnia (🧵 7/10)
In postmenopausal women with severe osteoporosis, romosozumab was not associated with higher 12-month cardiovascular risk than alendronate; a propensity‑matched real‑world study. G Teker et al. JBMM 30 Oct 2026 shorturl.at/wCBIX …reassuring ...prospective confirmation warranted
November 2, 2026 at 7:58 AM
In postmenopausal women with severe osteoporosis, romosozumab was not associated with higher 12-month cardiovascular risk than alendronate; a propensity‑matched real‑world study. G Teker et al. JBMM 30 Oct 2026 shorturl.at/wCBIX …reassuring ...prospective confirmation warranted
A 2025 European study of 841 adults reveals why women carry higher Alzheimer's risk: postmenopausal loss of estrogen impairs the brain's ability to maintain protective&he…
https://news.gmj.ge/briefs/announcement-blood-lipid-shifts-in-women-may-explain-higher-alzheimers-risk-european-study-suggests/
https://news.gmj.ge/briefs/announcement-blood-lipid-shifts-in-women-may-explain-higher-alzheimers-risk-european-study-suggests/
Announcement: Blood lipid shifts in women may explain higher Alzheimer’s risk, European study suggests
A 2025 European study of 841 adults reveals why women carry higher Alzheimer's risk: postmenopausal loss of estrogen impairs the brain's ability to maintain protective&he…
news.gmj.ge
November 2, 2026 at 3:27 AM
A 2025 European study of 841 adults reveals why women carry higher Alzheimer's risk: postmenopausal loss of estrogen impairs the brain's ability to maintain protective&he…
https://news.gmj.ge/briefs/announcement-blood-lipid-shifts-in-women-may-explain-higher-alzheimers-risk-european-study-suggests/
https://news.gmj.ge/briefs/announcement-blood-lipid-shifts-in-women-may-explain-higher-alzheimers-risk-european-study-suggests/
They describe clinical considerations for postmenopausal women receiving incretin-based therapies such as Nutritional optimisation, Physical activity, Role of bone monitoring with DEXA bone density scans or bone turnover markers…..
October 31, 2026 at 7:22 PM
They describe clinical considerations for postmenopausal women receiving incretin-based therapies such as Nutritional optimisation, Physical activity, Role of bone monitoring with DEXA bone density scans or bone turnover markers…..
Comparative efficacy and safety of pharmacological interventions for postmenopausal osteoporosis: a network meta-analysis
->Nature | More on "Osteoporosis treatment efficacy comparison" at BigEarthData.ai
->Nature | More on "Osteoporosis treatment efficacy comparison" at BigEarthData.ai
Comparative efficacy and safety of pharmacological interventions for postmenopausal osteoporosis: a network meta-analysis
This systematic review and NMA adhered to the Preferred Reporting Items for Systematic Review and Meta-Analyses for Network Meta-Analyses (PRISMA-NMA) guidelines. The completed checklist is provided in Supplementary Material 1. The study protocol was prospectively registered with PROSPERO (CRD420251149474). Data sources and search strategy We searched four English databases (PubMed, Embase, the Cochrane Library, and Web of Science) from their inception to March 5, 2026. The search strategy consisted of three main components: (1) Population (e.g., "post-menopausal bone loss", "post-menopausal osteoporosis", "post-menopause bone loss", "post-menopause osteoporosis"); (2) Intervention (e.g., "Alendronate", "Raloxifene", "Calcitonin", "Teriparatide", "Denosumab", "Calcitriol"); and (3) Study type (e.g., "Randomized Controlled Trial", "randomized", "placebo"). Only studies that were published in English were eligible for inclusion. The complete set of search queries is available in Supplementary Material 2. Inclusion criteria Publications were considered eligible for inclusion based on the criteria outlined below: (1) Study types: RCTs. (2) Population: Eligible participants were women aged ≥ 40 years with a diagnosis of postmenopausal osteoporosis, defined as either: the presence of a radiographic vertebral fracture or a recent (within 5 years) nonvertebral fracture, accompanied by a bone mineral density(BMD) T-score ranging from − 2.5 to − 5.0 in women ≤ 65 years or...
www.nature.com
November 2, 2026 at 2:10 PM
TLDR:
YES menopause due to cancer-related tx is more severe than natural menopause
OVARIAN SUPPRESSION is particularly severe
Post menopausal women CAN get additional symptoms, especially urogenital, due to suppression of residual hormones (adrenal and peripheral).
YES menopause due to cancer-related tx is more severe than natural menopause
OVARIAN SUPPRESSION is particularly severe
Post menopausal women CAN get additional symptoms, especially urogenital, due to suppression of residual hormones (adrenal and peripheral).
November 1, 2026 at 1:06 AM
TLDR:
YES menopause due to cancer-related tx is more severe than natural menopause
OVARIAN SUPPRESSION is particularly severe
Post menopausal women CAN get additional symptoms, especially urogenital, due to suppression of residual hormones (adrenal and peripheral).
YES menopause due to cancer-related tx is more severe than natural menopause
OVARIAN SUPPRESSION is particularly severe
Post menopausal women CAN get additional symptoms, especially urogenital, due to suppression of residual hormones (adrenal and peripheral).
Postmenopausal women who initiate off-label #TestosteroneTherapy experience a significantly elevated rate of incident #CVD, including heart failure and stroke, compared with unexposed women. Read more about this study presented at @menopausesociety.bsky.social here ⬇️ https://bit.ly/3US8yym
Cardiovascular Disease Risk Rises Significantly With Testosterone Use in Postmenopausal Women
Researchers evaluated the association between off-label testosterone therapy and incident cardiovascular disease in postmenopausal women.
www.clinicaladvisor.com
October 27, 2026 at 5:56 PM
Postmenopausal women who initiate off-label #TestosteroneTherapy experience a significantly elevated rate of incident #CVD, including heart failure and stroke, compared with unexposed women. Read more about this study presented at @menopausesociety.bsky.social here ⬇️ https://bit.ly/3US8yym